{"id":2143,"date":"2007-10-02T18:51:21","date_gmt":"2007-10-02T17:51:21","guid":{"rendered":"http:\/\/moomango.co.uk\/htb\/?p=2143"},"modified":"2013-09-12T16:14:03","modified_gmt":"2013-09-12T16:14:03","slug":"maraviroc-approved-in-europe-for-treatment-experienced-ccr5-tropic-patients","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/2143","title":{"rendered":"Maraviroc approved in Europe for treatment-experienced CCR5-tropic patients"},"content":{"rendered":"<p><strong>On 24 September 2007, maraviroc (trade name in Europe Celsentri) was approved in Europe for treatment-experienced patients who have CCR5-tropic HIV infection. Maraviroc is a CCR5 inhibitor manufactured by Pfizer with the trade name Celsentri in Europe and Selzentry in the US.<\/strong><\/p>\n<p>Maraviroc is the first member of a new class of oral HIV medicines (CCR5-antagonists) and works by blocking viral entry into human cells.<\/p>\n<p>EU approval of maraviroc is based on 48-week data from the two ongoing double-blind, placebo-controlled MOTIVATE clinical trials, which showed that maraviroc plus optimised background therapy (OBT) provided substantially greater viral load reduction compared to patients receiving OBT alone.<\/p>\n<p>Further details and product information are in the European Public Assessment Report on the web site of the European Medicines Agency.<\/p>\n<p>Celsentri &#8211; EMEA European Public Assessment Report <a href=\"http:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/celsentri\/celsentri.htm\"><br \/>\nhttp:\/\/www.emea.europa.eu\/humandocs\/Humans\/EPAR\/celsentri\/celsentri.htm<\/a><\/p>\n<p>Source: Pfizer press release, 24 September, 2007.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On 24 September 2007, maraviroc (trade name in Europe Celsentri) was approved in Europe for treatment-experienced patients who have CCR5-tropic HIV infection. Maraviroc is a CCR5 inhibitor manufactured by Pfizer with the trade name Celsentri in Europe and Selzentry in &hellip;<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3],"tags":[],"class_list":["post-2143","post","type-post","status-publish","format-standard","hentry","category-antiretrovirals"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2143","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=2143"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/2143\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=2143"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=2143"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=2143"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}